Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new study shows baricitinib slows type 1 diabetes progression in young patients, but effects reverse after stopping the drug.
A new study finds that baricitinib, a pill used for rheumatoid arthritis and alopecia, may slow type 1 diabetes progression in newly diagnosed patients aged 10 to 30.
After 48 weeks of daily treatment, participants showed preserved insulin-producing beta cell function, reduced blood sugar swings, and lower insulin needs.
However, benefits disappeared after stopping the drug, with blood sugar control and insulin use returning to placebo levels by week 96.
The drug, which calms overactive immune responses, was well-tolerated and taken orally.
Researchers say results are promising for future trials to see if long-term or early use could delay or prevent type 1 diabetes, with potential approval within five years if larger studies confirm effectiveness.
Findings are preliminary and not yet peer-reviewed.
Un nuevo estudio muestra que baricitinib ralentiza la progresión de la diabetes tipo 1 en pacientes jóvenes, pero los efectos se invierten después de suspender el medicamento.